Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Jab1/Csn5 overexpression correlates with poor survival in various cancers, including nasopharyngeal carcinoma (NPC), breast cancer, and hepatocellular carcinoma.
• Jab1/Csn5 contributes to NPC resistance to radiotherapy and cisplatin by influencing DNA damage and repair.
• The precise mechanism driving Jab1/Csn5 upregulation in NPCs remained undetermined.

Purpose of the Study:

• To identify the upstream regulator of Jab1/Csn5 expression in nasopharyngeal carcinoma.
• To elucidate the role of this regulator in the intrinsic resistance of NPC cells to cisplatin treatment.

Main Methods:

• Correlation analysis between Signal transducer and activator of transcription-3 (Stat3) and Jab1/Csn5 expression.
• In vitro and in vivo studies involving Stat3 silencing in NPC models.
• Analysis of Stat3 and Jab1 mRNA expression in The Cancer Genome Atlas (TCGA) and R2 databases.

Main Results:

• Stat3 expression correlates with and drives Jab1/Csn5 transcription.
• Silencing Stat3 in tumors reduced Jab1/Csn5 expression, enhancing NPC cell sensitivity to cisplatin-induced apoptosis.
• Stat3 transcriptionally regulates Jab1/Csn5.
• High Stat3 or Jab1 mRNA levels are associated with shorter survival in colon cancer, breast cancer, and glioblastoma.

Conclusions:

• A novel Stat3-Jab1/Csn5 signaling axis is identified in cancer pathogenesis.
• This axis holds significant therapeutic and prognostic relevance for multiple cancer types.
• Targeting the Stat3-Jab1/Csn5 pathway presents a potential strategy for overcoming cancer treatment resistance.